An Open-Label Pilot Study of the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily in Adult Subjects With Non-Segmental Facial Vitiligo
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2019
At a glance
- Drugs ATI 502 (Primary)
- Indications Vitiligo
- Focus Therapeutic Use
- Sponsors Aclaris Therapeutics
- 07 Jan 2019 Planned End Date changed from 12 Nov 2018 to 30 Sep 2019.
- 07 Jan 2019 Planned primary completion date changed from 12 Nov 2018 to 30 Sep 2019.
- 07 Jan 2019 Status changed from recruiting to active, no longer recruiting.